• New Delhi
  • 10 March 2014
  • Interviews
  • By Rahul Koul

“We are well positioned in India”

Mr Paul A Smaltz, executive vice president-pharmaceuticals, Avantor Avantor Performance Materials sees great potential in India's growing market. Here he highlights various aspects of company’s India focused activities


Mr Paul A Smaltz, executive vice president-pharmaceuticals, Avantor Performance Materials

After the takeover of New Delhi based biosupplier RFCL's business in 2011, the Avantor Performance Materials, a global supplier of high-performance chemistries and materials to the biopharmaceutical industries, has expanded its footprint significantly in India. Here are the excerpts of the recent interview with one of the company's top executive, Mr Paul A Smaltz.

Q: It has been three years since the acquisition of RFCL by Avantor. How has it benefitted the company operations in India?

The acquisition of  RFCL by Avantor has allowed the company to build a solid position in the Indian market as a supplier of high-quality, fully traceable regulated raw materials to the traditional small-molecule market, as well as the growing large-molecule segment.

Thanks to excellent local management and logistics support from the RFCL team, Avantor was able to enter the market as a key supplier of multi-compendia cGMP-produced materials (current Good Manufacturing Practices) by initially importing its JT Baker brand products from the US to supply the fast-growing pharmaceutical market in India.

Avantor then completed a state-of-the-art pharmaceutical raw material facility in Panoli, India, which began cGMP production in January 2013. This facility is ISO 9001:2008 registered; approved by the Indian FDA; and registered with the US FDA.


Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email